Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 8/20 | 0.41 |
| ▸ | NCEH1 | Q6PIU2 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | FPR3 | P25089 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30175909 | 1.00 | AAK1 (0.41) | AAK1NCEH1NPC1RECQLRAB9A | |
| SCHEMBL20671184 | 0.88 | AAK1 (0.40) | AAK1NCEH1NPC1RECQLRAB9A | |
| SCHEMBL16096043 | 0.88 | AAK1 (0.40) | AAK1NCEH1NPC1RECQLRAB9A | |
| SCHEMBL30116140 | 0.88 | AAK1 (0.40) | AAK1NCEH1NPC1RECQLRAB9A | |
| SCHEMBL28896606 | 0.86 | ALDH1A1 (0.45) | AAK1NCEH1NPC1RECQLRAB9A | |
| SCHEMBL30829434 | 0.86 | ALDH1A1 (0.45) | AAK1NCEH1NPC1RECQLRAB9A | |
| SCHEMBL27634058 | 0.86 | AAK1 (0.49) | AAK1NCEH1NPC1RECQLRAB9A | |
| SCHEMBL4015276 | 0.86 | SIRT2 (0.43) | AAK1NCEH1NPC1RAB9ASMN1; SMN2 | |
| Methane SCHEMBL27428599 | 0.84 | POLB (0.40) | AAK1NCEH1SMN1; SMN2ALDH1A1PTGDR2 | |
| SCHEMBL21789125 | 0.83 | NR4A2 (0.41) | AAK1NCEH1NPC1RECQLRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11730055-B2 | Dopant, charge transfer salt and organic electronic device | CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| US-11730055-B2 | Dopant, charge transfer salt and organic electronic device | CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| WO-2017103610-A1 | DOPANT, CHARGE TRANSFER SALT AND ORGANIC ELECTRONIC DEVICE | CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) | 2017-06-22 | — | — | WO | disclosed |
| WO-2017103609-A1 | CHARGE TRANSFER SALT, ELECTRONIC DEVICE AND METHOD OF FORMING THE SAME | CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730055-B2 | Dopant, charge transfer salt and organic electronic device | CHRM1, SLC6A3, DRD1 | AAK1 4095/4885NCEH1 914/4885NPC1 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.